Takeda To Cut Costs By ¥100 Billion Globally By 2017
This article was originally published in PharmAsia News
Executive Summary
Takeda President Yasuchika Hasegawa expressed confidence in the growth of the company, stating that despite patent expiration for type 2 diabetes drug Actos and exchange rate fluctuations, sales in the last three months have grown 5% compared to the same time last year.